cancer

A change of the guard for the world’s biggest cancer companies
A change of the guard for the world’s biggest cancer companies
EP Vantage
cancer
Bristol-Myers Squibb
Celgene
M&A
Roche
AstraZeneca
Flag link:
Mirati sets date for closely watched clinical KRAS readout
Mirati sets date for closely watched clinical KRAS readout
Fierce Biotech
Mirati Therapeutics
KRAS
MRTX849
Amgen
cancer
Flag link:
Sean Parker-Backed ArsenalBio Wants To Create Better Weapons Against Cancer
Sean Parker-Backed ArsenalBio Wants To Create Better Weapons Against Cancer
Forbes
ArsenalBio
precision medicine
cancer
CRISPR
Sean Parker
Flag link:
Helping Cancer Patients Navigate Clinical Trials
Helping Cancer Patients Navigate Clinical Trials
BioSpace
clinical trials
patients
cancer
Flag link:
Pfizer scrambles to fill void after Teva stops making chemo drug often given to children
Pfizer scrambles to fill void after Teva stops making chemo drug often given to children
Fierce Pharma
Pfizer
Teva Pharmaceutical
chemotherapy
cancer
pediatrics
vincristine
Flag link:
Forbius completes enrollment into phase 1a solid tumour trial of AVID200
Forbius completes enrollment into phase 1a solid tumour trial of AVID200
Pharmaceutical Business Review
Forbius
fibrosis
cancer
AVID200
solid tumors
clinical trials
Flag link:
Boehringer's VC wing backs anti-cancer virus startup
Boehringer's VC wing backs anti-cancer virus startup
Fierce Biotech
Abalos Therapeutics
arenavirus
Boehringer Ingelheim
cancer
Flag link:
Q&A: Adaptimmune’s Elliot Norry on cell therapy
Q&A: Adaptimmune’s Elliot Norry on cell therapy
Pharmaforum
cell therapy
cancer
Adaptimmune
Flag link:
Big Pharma Bets on Body’s Garbage-Disposal System to Beat Cancer
Big Pharma Bets on Body’s Garbage-Disposal System to Beat Cancer
Bloomberg
cancer
Arvinas
Kymera
targeted protein degradation
Flag link:
New Class of Drugs Could Help Treat Resistant Cancers
New Class of Drugs Could Help Treat Resistant Cancers
BioSpace
cancer
Institute of Cancer Research
BOS172722
Flag link:
3 Drug Stocks Poised for Gains After Cancer Conference
3 Drug Stocks Poised for Gains After Cancer Conference
Investopedia
ESMO
cancer
Amgen
Incyte
Bristol-Myers Squibb
Flag link:
As developers work on cracking KRAS, Germany's Boehringer has quietly begun testing its pan-KRAS drug in humans
As developers work on cracking KRAS, Germany's Boehringer has quietly begun testing its pan-KRAS drug in humans
Endpoints
KRAS
cancer
Boehringer Ingelheim
Flag link:
Early Research Could Lead the Way to a Universal Cancer Vaccine
Early Research Could Lead the Way to a Universal Cancer Vaccine
BioSpace
cancer
cancer vaccines
universal cancer vaccine
Arizona State University
R&D
Flag link:
ElevateBio founds HighPassBio to develop Fred Hutch cell therapy
ElevateBio founds HighPassBio to develop Fred Hutch cell therapy
Fierce Biotech
ElevateBio
HighPassBio
cancer
cell therapy
leukemia
Flag link:
Dana-Farber Study Confirms Accuracy of GRAIL's Blood Test for Cancer
Dana-Farber Study Confirms Accuracy of GRAIL's Blood Test for Cancer
BioSpace
diagnostics
Grail
Dana-Farber
cancer
Flag link:
Shiny, new and expensive: ESMO studies find new cancer drugs carry higher prices, add little benefit
Shiny, new and expensive: ESMO studies find new cancer drugs carry higher prices, add little benefit
Fierce Pharma
cancer
ESMO
drug pricing
oncology
Flag link:
Pfizer expands real-world data collaboration with Flatiron Health
Pfizer expands real-world data collaboration with Flatiron Health
Pharmaceutical Business Review
Pfizer
Flatiron Health
oncology
real world data
cancer
Flag link:
Overcoming Cancer Drug Resistance with A Bispecific Inhibitor
Overcoming Cancer Drug Resistance with A Bispecific Inhibitor
Xtalks
oncology
drug resistance
Kitov
cancer
bispecific antibodies
Flag link:
Merck, Pfizer execs explain how they tap sites for cancer trials
Merck, Pfizer execs explain how they tap sites for cancer trials
Biopharma Dive
cancer
clinical trials
Pfizer
Merck
immuno-oncology
Bavencio
Keytruda
Flag link:
Bayer’s Vitrakvi is first tumour-agnostic drug approved in EU
Bayer’s Vitrakvi is first tumour-agnostic drug approved in EU
Pharmaforum
Bayer
TRK inhibitors
Vitrakvi
Europe
tumor agnostic drugs
cancer
Flag link:

Pages